Background

Lanthanide-doped nanoparticles are potential candidates for photodynamic therapy (PDT) owing to their chemical and optical features. Following irradiation by X-ray or UV light, these scintillating nanoparticles emit light matching the photosensitizer absorption spectrum. These properties allow both targeted cancer therapy and deep cancer treatment.

Methods and results

LaF₃: Tb³⁺ nanoparticles were synthesized and characterized before conjugation to the photosensitizing agent, meso-tetra (4-carboxyphenyl) porphine (MTCP) or its copper form (CuMTCP). Photosensitizer conjugated LaF₃:Tb³⁺ nanoparticles were readily taken up by the cells. The cytotoxic effect of drug-conjugated nanoparticle as PDT mediator and its precursors were examined on the breast (T47D) and prostate (LNCap) cancer cell lines. Neither of the molecules showed cytotoxicity at the dark condition. Cell viability was also measured after brief exposure to safe doses of UV light or X-ray to evaluate the effectiveness for surface and deep tumor therapy, respectively. Viability testing confirmed that while the nanoparticles and photosensitizing agents had minimal toxicity under UV light or X-ray, MTCP-conjugated LaF₃:Tb³⁺ nanoparticles significantly reduced cell viability. Conjugation of folic acid to photosensitizer-LaF₃:Tb³⁺ nanoparticles as a targeting molecule did not show interference with the toxicity of the system assuring the suitability of MTCP-LaF₃:Tb³⁺ nanoparticles for targeted therapy of deep and surface cancers.

Conclusion

MTCP-LaF₃:Tb³⁺ nanoparticles are lethal upon activation by UV light or X-ray allowing their usage for surface and deep cancer targeted therapy. The conjugation of MTCP–LaF₃:Tb³⁺ nanoparticles to folic acid as a targeting agent for cancer therapy does not reduce the cytotoxicity of this system.

中文翻译：

---

LaF3：Tb3+ 纳米颗粒显示出对靶向治疗的适应性，可实现更安全的癌细胞治疗

背景

由于其化学和光学特性，镧系元素掺杂的纳米粒子是光动力疗法 (PDT) 的潜在候选者。在 X 射线或紫外线照射后，这些闪烁的纳米粒子发出与光敏剂吸收光谱相匹配的光。这些特性允许靶向癌症治疗和深度癌症治疗。

方法和结果

LaF ₃：Tb ³⁺纳米颗粒在与光敏剂、内消旋四（4-羧基苯基）卟吩（MTCP）或其铜形式（CuMTCP）结合之前被合成和表征。光敏剂共轭 LaF ₃ :Tb ³⁺纳米颗粒很容易被细胞吸收。在乳腺癌 (T47D) 和前列腺 (LNCap) 癌细胞系上检查了药物偶联纳米颗粒作为 PDT 介质及其前体的细胞毒性作用。在黑暗条件下，这两种分子都没有表现出细胞毒性。在短暂暴露于安全剂量的紫外线或 X 射线后，还测量了细胞活力，以分别评估表面和深层肿瘤治疗的有效性。活力测试证实，虽然纳米颗粒和光敏剂在紫外线或 X 射线下具有最小的毒性，但 MTCP 偶联的 LaF ₃ :Tb ³⁺纳米颗粒显着降低了细胞活力。叶酸与光敏剂-LaF ₃ :Tb ^{3+ 的结合}纳米粒子作为靶向分子没有显示干扰系统的毒性，确保 MTCP-LaF ₃ :Tb ³⁺纳米粒子适用于深层和表面癌症的靶向治疗。

结论

MTCP-LaF ₃ :Tb ³⁺纳米粒子在被紫外线或 X 射线激活后是致命的，因此可用于表面和深层癌症靶向治疗。MTCP–LaF ₃ :Tb ³⁺纳米颗粒与叶酸的结合作为癌症治疗的靶向剂不会降低该系统的细胞毒性。